TP53 and neoplasm: We have demonstrated that a potent and selective small-molecule inhibitor of the p53-MDM2 binding, nutlin-3a, can stabilize p53 and activate the p53 pathway in a broad panel of wild-type tumor lines including prostate [26,27].